What Are Short-Chain Fatty Acids?
Short-chain fatty acids (SCFAs) are organic acids with fewer than six carbon atoms — primarily acetate (C2), propionate (C3), and butyrate (C4). They are produced in the colon when anaerobic bacteria ferment dietary fibres, resistant starches, and other complex carbohydrates that escape digestion in the small intestine. In a typical Western diet, the colon produces roughly 500–600 mmol of SCFAs per day, with a molar ratio of approximately 60:20:20 (acetate:propionate:butyrate).
Butyrate: Fuel for the Colonocyte
Butyrate is the preferred energy substrate for colonocytes — the epithelial cells lining the colon. It supplies approximately 70% of their energy needs through mitochondrial β-oxidation. This metabolic dependency has profound implications: when butyrate production falls (due to dysbiosis, low-fibre diets, or antibiotic exposure), colonocyte metabolism shifts, epithelial tight junctions loosen, and mucosal barrier integrity declines. The resulting increase in intestinal permeability permits translocation of bacterial products (lipopolysaccharide, peptidoglycan) into the lamina propria, triggering low-grade immune activation.
Immune Modulation
Beyond energy provision, butyrate and propionate are potent histone deacetylase (HDAC) inhibitors. By acetylating histones, they modify gene expression in immune cells — promoting the differentiation of regulatory T cells (Tregs), suppressing NF-κB-mediated pro-inflammatory cytokine production, and enhancing tolerogenic dendritic-cell responses. This epigenetic regulation helps explain why high-fibre diets are consistently associated with reduced systemic inflammation in epidemiological studies.
Propionate and Metabolic Signalling
Propionate, absorbed into the portal circulation, reaches the liver where it serves as a substrate for gluconeogenesis and inhibits cholesterol synthesis. In peripheral tissues, propionate and acetate activate free fatty acid receptors (FFAR2/GPR43 and FFAR3/GPR41), modulating appetite signalling, insulin sensitivity, and adipose-tissue inflammation. These pathways are under active investigation as potential targets for metabolic-syndrome interventions.
Clinical Relevance
Reduced faecal SCFA concentrations have been documented in IBS, IBD, colorectal cancer, obesity, and type 2 diabetes. However, the causal direction remains debated: do low SCFAs drive disease, or does disease drive low SCFAs? Interventional trials with prebiotic fibre supplementation (inulin, fructo-oligosaccharides) show consistent increases in faecal butyrate and improvements in epithelial barrier markers, but clinical symptom outcomes are variable — underscoring that SCFAs operate within a complex ecosystem, not as a simple dose-response pharmaceutical.
Dietary Implications
The most reliable way to increase colonic SCFA production is to consume a diverse, fibre-rich diet: whole grains, legumes, vegetables, and fermented foods provide the substrates that SCFA-producing taxa (particularly Faecalibacterium prausnitzii, Roseburia, and Eubacterium rectale) require. Supplementing a single prebiotic in the context of an otherwise low-fibre diet produces modest, often transient effects — reinforcing that the microbiome responds to dietary patterns, not magic bullets.